dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
Published 5 years ago • 251 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
0:51
dr. pal on the safety profile of cabozantinib/atezolizumab in advanced rcc
-
3:16
optimizing the use of ipilimumab/nivolumab in mrcc
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
0:43
dr. pal on sequencing nivolumab in rcc
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
4:48
renal cell carcinoma: everything you need to know
-
7:52
frontline treatment options for stage 4 rcc
-
31:14
current treatment of advanced renal cell carcinoma, christian kollmannsberger, md
-
1:01
dr. pal on sequencing challenges for the treatment of patients with rcc
-
1:22
dr. pal on cohort findings of cosmic-021 trial in mcrpc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
0:52
dr. mckay on fda approval of nivolumab/ipilimumab in frontline rcc
-
2:00
nivolumab and ipilimumab in mrcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
0:29
dr. mckay on fda approval of frontline cabozantinib in rcc
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
0:48
dr. pal on preoperative immunotherapy in patients with rcc